Adherence rates and health care costs in Crohn’s disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data

BACKGROUND: Patient support programs have a positive effect on adherence to therapy. Certolizumab pegol (CZP) is a tumor necrosis factor antagonist for the treatment of Crohn’s disease. OBJECTIVES: To assess, using real-world claims data, whether home health nurse assistance had an effect on patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Douglas C, Jaganathan, Srihari, Burudpakdee, Chakkarin, Seetasith, Arpamas, Low, Robert, Lee, Edward, Gucky, Jay, Yassine, Mohamed, Schwartz, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973629/
https://www.ncbi.nlm.nih.gov/pubmed/29872272
http://dx.doi.org/10.2147/PPA.S148777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973629/
https://www.ncbi.nlm.nih.gov/pubmed/29872272
http://dx.doi.org/10.2147/PPA.S148777

Ejemplares similares